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Abstract
Background: Dopamine transporter (DaT) 123I–FP-CIT scans most commonly are
interpreted visually. Alternatively, absolute quantitation of radiopharmaceutical
uptake may improve scan accuracy. However, neither approach accomodates
dependence of striatal uptake on age and gender. We investigated whether
demographic indexing of visual and numerical variables improve discrimination of
patients with essential tremor (ET), Parkinson’s disease (PD), and dementia with Lewy
bodies (DLB).
Methods: Data of 132 consecutive patients undergoing DaT SPECT scans were
reviewed retrospectively. The clinical impression in the latest neurology note was
utilized as the final clinical diagnosis. Caudate and putamen specific binding ratio
(PSBR) were computed. 123I calibration phantoms were constructed to enable
absolute quantitation of putamen radiopharmaceutical uptake. A single
experienced nuclear medicine physician graded visual certainty on a 3-level scale.
Demographic indexing normalized metrics to published normal PSBR values.
Methods were compared by simultaneous ROC analyses to identify the technique
of maximal accuracy.
Results: Thirty-four patients (26%) were diagnosed with ET, 85 (64%) with PD, 6
(5%) with multiple system atrophy, and 7 (5%) with DLB. For discriminating DLB
from PD, visual analysis was significantly less specific and accurate than the other
techniques. However, indexing significantly improved specificity and accuracy of
visual scores, such that indexed visual scores were statistically equivalent to all
other methods. Indexed PSBR yielded essentially the same results as non-indexed
PSBR, for which highest overall test efficacy was achieved.
Conclusions: Our results in this small series of patients with DLB suggest that if
123I–FP-CIT visual scores are to be used to discriminate DLB from other neurologic
disorders, demographic indexing should be applied. However, best results overall
are obtained using quantified parameters, regardless of whether or not
demographic indexing is applied to these values.
Keywords: 123I–ioflupane, Dementia with Lewy bodies, Parkinson’s disease,
Dopamine transporters, DaT, Brain SPECT
Background
Dopamine transporter (DaT) 123I–ioflupane scans are performed to help discriminate
patients with essential tremor (ET), for which radiopharmaceutical uptake is intense
and symmetric in caudate and putamen structures, from patients with Parkinson’s
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syndrome (PS). DaT scans utilize the radioligand [123I] N-x-flouropropyl-2b-carbo-
methoxy-3b-(4-iodophenyl) nortropane (FP-CIT) and single photon emission computed
tomography (SPECT) to detect dopaminergic dysfunction in the brain. FP-CIT binds to
DaT, a presynaptic protein in nigrostriatal neurons responsible for dopamine reuptake
from the synapatic cleft. DaT are found in high concentrations in the striatum (caudate
and putamen). Loss of nigrostriatal neurons results in decreased dopamine concentra-
tions in the striatum, and DaT levels correlate with dopamine concentrations in the
striatum (Kish et al., 1988; Andringa et al., 2005). Nigrostriatal neuronal dysfunction or
loss of substantia nigra neuronal cell bodies results in reduced binding of FP-CIT
(Walker & Walker, 2009). In Parkinson’s disease, loss of dopaminergic activity is pro-
gressive and first occurs in the contralateral putamen (Marshall & Grosset, 2003).
Parkinson’s disease (PD), however, is not the only cause of PS; other causes include
progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, and
dementia with Lewy bodies (DLB) (Fig. 1) (Marshall & Grosset, 2003). DLB is the sec-
ond most common form of neurodegenerative dementia, after Alzheimer’s disease, ac-
counting for 4–8% of all newly diagnosed dementia cases (Vann Jones & O’Brien, 2014;
van der Zande et al., 2016). DLB is caused by abnormal deposition of alpha-synuclein
protein in dopaminergic nigrostriatal neurons as well in other portions of the brain.
The core clinical features of DLB include fluctuating cognition, visual hallucinations,
and movement symptoms. As such, the clinical presentation of DLB overlaps with
Parkinson’s disease as well as with Alzheimer’s disease, compromising the ability to
form a definitive diagnosis (van der Zande et al., 2016). While patients with DLB and
Alzheimer’s have similar symptoms in early disease stages, the course of these diseases
and their management is substantially different for patients with DLB from those with
Alzheimer’s (Bostrom et al., 2007a; Bostrom et al., 2007b).
The main use of DaT scanning is in patients with a movement disorder to help differen-
tiate ET from tremor due to neurodegenerative parkinsonism, but DaT scans also are used
to help differentiate patients with DLB from those with Alzheimer’s (Walker et al., 2015).
Whereas an abnormal DaT scan has been included as a suggestive diagnostic feature for
DLB (McKeith et al., 2005), a normal DaT scan is consistent with Alzheimer’s disease, ET,
drug-induced parkinsonism, or in some cases vascular parkinsonism (Gerschlager et al.,
2002; Sixel-Döring et al., 2011; Djang et al., 2012; Utiumi et al., 2012).
Fig. 1 DaT scan examples. DaT scan transaxial SPECT sections for: (a) a patient with essential tremor,
showing high symmetric uptake in both caudate and putamen regions; (b) a patient with Parkinson’s
disease, showing markedly reduced putamen activity and asymmetric caudate activity; (c) a patient with
dementia with Lewy bodies, showing nearly absent caudate and putamen uptake
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DaT SPECT scans most commonly are interpreted visually, and scoring systems have
been proposed to aid in qualitative evaluation (Benamer et al., 2000). Absolute quanti-
tation of radiopharmaceutical uptake has the potential to improve accuracy of nuclear
tomography (Gnesin et al., 2016). However, neither use of visual scores nor absolute
quantitation takes into account observed dependence of caudate and putamen uptake
on age and gender (Nobili et al., 2013). Therefore, we conducted this investigation to
determine whether demographic indexing, i.e., adjusting visual scores and quantitative
uptake measurements for previously documented DaT SPECT scan differences associ-
ated with age and gender, can improve discrimination of patients with PD from those
with DLB.
Methods
Compliance with ethical standards
The Institutional Review Board approved this retrospective study and the requirement
to obtain informed consent was waived (IRB #: 13-139B). All data were handled in
compliance with the Health Insurance Portability and Accountability Act of 1996. None
of the authors have any conflicts of interest to disclose in relation to this investigation.
Patients
From August 2011 through July 2016, 280 consecutive patients who underwent
DaT scanning at our institution were reviewed retrospectively. The clinical indica-
tion for all examinations was movement disorder. Clinical follow-up was obtained
primarily through institutional ambulatory electronic health records. Follow-up was
successfully obtained for 132 patients (68 ± 11 years; 76 males; 56 females). For
each patient, all neurology clinic notes prior to and after the DaT scan were
reviewed. The clinical impression in the latest neurology note was utilized as the
presumptive final clinical diagnosis. For each patient, age and sex were tabulated at
the time of the DaT scan. The amount of injected activity for each patient was
obtained from the Division of Nuclear Medicine and Molecular Imaging patient
charts, to enable quantitation of absolute uptake.
Data acquisition
Patients were pretreated with Lugol's solution approximately one hour before radiophar-
maceutical administration. SPECT imaging was performed 3–5 h after IV injection of
185 MBq (5 mCi) of 123I–FP-CIT, according to standardized guidelines (Darcourt et al.,
2010). Data were acquired according to the manufacturer’s suggested protocol, employing
a 15% energy window centered at 159 keV, 128 × 128 matrixes, zoom factor of 1.0, pixel
size of 4.66 mm, at 30 s/projection for 128 projections, for a total acquisition time of 34–
35 min, using low energy high resolution collimators. The same dual detector rotating
gamma camera system (Skylight, Philips Inc.) was used for all patient acquisitions. All
tomograms were reconstructed by filtered backprojection (with Butterworth cutoff = 0.5
and order = 8) as per the manufacturer, and corrected for attenuation by the Chang
method (linear attenuation coefficient μ = 0.11).
To enable absolute quantitation of radiopharmaceutical uptake, phantoms were con-
structed using 1.7–7.0 MBq (20–80 μCi) 123I in saline in four 5-mL syringes to simulate
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caudate nuclei and putamina in a 6000 mL water phantom with 123I background activ-
ity (Fig. 2a). Each syringe was filled with activity for 1 mL of its 5 mL volume to simu-
late left and right caudate nuclei and putamina. The same gamma camera system used
for all patient data acquisitions was used for all phantom acquisitions. Seven simula-
tions were performed to replicate typical image data acquired for patients with ET,
using identical data acquisition and tomographic reconstruction procedures as was per-
formed for clinical data, with the only exception being that times per projection were
adjusted to provide simulated striatal and background counts typical of mean clinical
counts (Fig. 2b and c).
Quantitative parameters
To obtain striatal counts, a medical physicist manually drew regions of interest on all
clinical scans and phantom simulations to determine caudate, putamen and back-
ground counts. The relative measurement of caudate-to-background specific binding
ratio (CSBR) was computed as:
CSBR ¼ C−Bð Þ=B ð1Þ
where B is background counts per pixel and C is the minimum of left or right caudate
mean count per pixel. The relative measurement of putamen-to-background specific
binding ratio (PSBR) was computed similarly as:
PSBR ¼ P−Bð Þ=B ð2Þ
where P is the minimum of left or right putamen mean counts per pixel.
Reconstructed phantom data were used to calibrate caudate absolute quantitation
(CAQ) and putamen absolute quantitation (PAQ). As with CSBR and PSBR ratios de-
fined above, the minimum of left or right mean striatal counts were used for caudal
and putaminal counts. Both CAQ and PAQ were corrected for mean background
counts. Because there was a range of injected activities for clinical studies, the physical
unit chosen for absolute quantitation was the percent uptake of injected activity per
mL of brain tissue. Patient caudate nuclei and putamina each were assumed to have a
volume of 1 mL. The ratio of counts per pixel in the caudate nuclei and putamina for
clinical studies versus phantom studies then yielded estimates of absolute quantitation
of percent uptake of injected activity per mL.
Fig. 2 Physical phantom. a Physical phantom with syringes loaded with radioactivity representing caudate
(C) and putamen (P) structures, and radioactivity loaded into surrounding water background (B).
Reconstructed phantom images for simulations representing (b) essential tremor and (c) Parkinson’s disease
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Demographic indexing
To apply demographic indexing, all metrics were normalized to CSBR and PSBR values
that have been published for normal volunteers (Nobili et al., 2013). This was accom-
plished using published expected values of striatal-to-background count ratios:
Normal CSBR ¼ 6:8–0:0273age for males ð3Þ
Normal CSBR ¼ 7:232–0:0273age for females ð4Þ
Normal PSBR ¼ 6:702–0:0339age for males ð5Þ
Normal PSBR ¼ 7:116–0:0339age for females ð6Þ
Each CSBR and PSBR value was divided by the expected value for a normal subject
of the age and gender of the patient. In addition to indexing ratios of striatal counts to
background counts, we also examined indexed CAQ, indexed PAQ, and indexed visual
scores using these same normalizing factors (Eqs. 3–6), which required inherently
assuming that background counts are not dependent on age.
Visual readings
A single nuclear medicine physician, with more than 20 years experience in the field and
more than 7 years experience in reading (superscript)123-I ioflupane studies, graded all clin-
ical studies, blinded to previous reports, final diagnoses, and quantified parameters and stud-
ies. The assigned grades on a 3-point scale were: 0 = “definitely normal,” 1 = “equivocal,” and
2 = “definitely abnormal.” The same physician also dichotomously graded each scan as visu-
ally appearing to have symmetric or asymmetric striatal uptake.
To form an hybrid score combining visual scores with information as to gender and
age dependence of 123I–FP-CIT, we divided the visual score by the normal PSBR value
for males or females (Eqs. 5 and 6), in order to obtain the indexed visual score.
Statistics
All values are reported as means with 1 standard deviation. Analysis of variance
(ANOVA) tested multiple variables simultaneously to detect differences among disease
categories. The normality of distributions of continuous variables was assessed by the
chi-square test. The t-test was used to detect differences between means of normal dis-
tributions; otherwise, the Wilcoxon test was used. Chi-square analysis of proportions
was used to determine if ratios were significantly different. Power analyses were used to
determine if differences were significant for patient sub-groups with small sample sizes.
Linear regression was used to test whether background counts were correlated with
age. ROC analyses were performed to analyze the ability of different metrics to discrim-
inate groups of patients by disease states. ROC analyses provided discrimination thresh-
olds to dichotomize variables, from which sensitivity, specificity and accuracy were
determined. All analyses were performed using commercially available software
(MedCalc Statistical Software version 18 (MedCalc Software bvba, Ostend, Belgium;
http://www.medcalc.org; 2018)).
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Results
Mean follow up time from DaT scans to final diagnoses was 1.3 ± 1.1 yrs., at which time
34 (26%) had ET, 85 (64%) had PD, 6 (5%) had multiple system atrophy, and 7 patients
(5%) had DLB.
Background counts were uncorrelated with age, both for all patients (r = − 0.08, p =
0.33) and for the subgroup of patients with ET (r = − 0.09, p = 0.58). ANOVA showed no
differences in background counts among disease groups (F-ratio = 1.1, p = 0.37), nor were
background counts different between male and female patients with ET (108 ± 23 versus
110 ± 27 counts/pixel, p = 0.38), so that the assumption of independence of background
counts with age and sex were considered to be valid for subsequent analyses.
Discriminating ET from other disease states
ANOVA demonstrated that visual scores, CSBR, PSBR, CAQ and PAQ all were signifi-
cantly different among disease states (p < 0.001), with F-ratios > 12.1. The highest F-ratio
(41.2) was found for indexed PSBR, indicating this metric had the greatest inter-group
variability (Table 1, Fig. 3). All metrics were significantly different between ET and all
other disease states. Patients with ET had mean age of 70 ± 11 yrs. (range: 49–88 years),
for whom CSBR was 2.08 ± 0.52 and PSBR was 1.24 ± 0.42. Several metrics were different
between patients with DLB and those with PD, but none were different between patients
with MA and DLB (Table 1).
For discriminating patients with ET from patients with PD, or for discriminating
patients with ET from patients with all other disease states, ROC analyses indicated
that PSBR had the highest accuracy of 86–87% (Tables 2 and 3). Specificity was signifi-
cantly lower for visual readings, CAQ, PAQ and indexed visual readings compared to
89% specificity of PSBR (Tables 2 and 3).
Discriminating patients with DLB
Indexed CAQ was the metric with the highest dichotomous accuracy to discriminate
patients with DLB from those with PD (Table 4). All metrics had similar sensitivity
Table 1 Visual and quantitative parameters for disease states
ET
(N = 34)
PD
(N = 85)
MA
(N = 6)
DLB
(N = 7)
ANOVA
F-ratio
Visual 0.81 ± 0.86 1.77 ± 0.55* 2.00 ± 0.00* 1.86 ± 0.38* 18.9
CSBR 2.08 ± 0.52 1.30 ± 0.54* 0.53 ± 0.23*† 0.80 ± 0.25*† 28.5
PSBR 1.24 ± 0.42 0.51 ± 0.36* 0.22 ± 0.17*† 0.28 ± 0.18*† 38.9
CAQ 5.34 ± 2.04 3.8 ± 1.76* 1.81 ± 1.39*† 1.94 ± 1.12*† 12.1
PAQ 2.11 ± 1.06 0.94 ± 0.61* 0.59 ± 0.49* 0.45 ± 0.40*† 23.8
Indexed Visual 0.18 ± 0.19 0.39 ± 0.13* 0.44 ± 0.02* 0.44 ± 0.09*† 17.2
Indexed CSBR 0.42 ± 0.11 0.25 ± 0.11* 0.10 ± 0.04* 0.16 ± 0.05* 29.7
Indexed PSBR 0.28 ± 0.09 0.11 ± 0.08* 0.05 ± 0.04* 0.07 ± 0.05* 41.2
Indexed CAQ 5.31 ± 1.09 3.67 ± 1.67* 1.74 ± 1.34*† 1.98 ± 1.11*† 13.2
Indexed PAQ 2.38 ± 1.27 1.02 ± 1.27* 0.64 ± 1.27* 0.53 ± 0.48*† 24.3
ET essential tremor, PD Parkinson’s disease, MA multiple system atrophy, DLB dementia with Lewy bodies, ANOVA analysis
of variance, CSBR caudate specific binding ratio, PSBR putamen specific binding ratio, CAQ minimum caudate absolute
quantitative uptake, PAQ minimum putamen absolute quantitative uptake
* p < 0.05 versus ET; † p < 0.05 versus PD
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(57%–100%). With only 7 cases of patients with DLB, power analysis indicated there
were insufficient cases to detect significant differences among metrics for sensitivity,
but also indicated that differences for specificity and accuracy were statistically
significant. Visual readings, CSBR and indexed CSBR measurements had significantly
lower specificity than the 92% specificity of Indexed CAQ (Table 4). The improvement
in specificity of visual scores by demographic indexing was significant (6% versus 86%,
p < 0.0001).
Similarly, Indexed CAQ was the most accurate means of discriminating patients with
DLB from patients with all other disease states (Table 5). Specificity of visual readings,
CSBR and indexed CSBR measurements were significantly lower than the 90% specificity
of Indexed CAQ (Table 5), but indexed visual scores had significantly higher specificity
than non-indexed visual scores (88% versus 31%, p < 0.0001) (Table 5, Fig. 4).
Fig. 3 Putamen specific binding ratios. Putamen specific binding ratio (PSBR) plotted for patients with
essential tremor (ET), Parkinson’s disease (PD), multiple system atrophy (MA) and dementia with Lewy
bodies (DLB)
Table 2 ROC result for discriminating patients with ET from those with PD
Threshold for discrimination Sensitivity Specificity Dichotomous Accuracy
Visual > 1 82% 72%* 79%
CSBR < 1.56 79% 86% 81%
PSBR < 0.76 85% 89% 86%
CAQ < 4.73 78% 56%* 71%*
PAQ <=1.70 87% 67%* 81%
Indexed Visual > 0.24 85% 72%* 81%
Indexed CSBR < 0.31 77% 86% 79%
Indexed PSBR <=0.15 79% 92% 83%
Indexed CAQ <=4.96 54%* 81% 62%*
Indexed PAQ <=1.65 82% 75% 81%
*p < 0.05 versus PSBR
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Discussion
Neither demographic indexing nor use of absolute quantitation improved ability to dis-
criminate patients with DLB compared to conventional putamen specific binding ratios.
Nonetheless, we found that while visual scores were not as specific or as accurate as
quantitative measures for discriminating patients with DLB from other neurologic dis-
eases, demographic indexing to produce a hybrid visual score did significantly improve
test specificity, to the point that indexed visual scores were statistically equivalent to
quantified metrics for this purpose. As shown in Fig. 4, demographic indexing effect-
ively stretched and adjusted the range of visual measurements, producing more distinct
differences among disease states, as compared to non-indexed visual scores.
In our study, the most common indication for DaT scan was to discriminate essential
tremor from neurodegenerative Parkinsonism. Diagnostic uncertainty is not uncommon
with clinical evaluation. The literature indicates that DaT scans are useful, particularly in
patients who present with unclear or atypical symptoms. In a 3-year prospective study,
initial clinical diagnosis of Parkinson’s disease was found to have a specificity of 46% and
sensitivity of 93% when compared to diagnosis after 3 year clinical follow-up, compared
to 97% and 78% with an initial DaT scan (Cummings et al., 2011). In another study, DaT
scan was shown to have sensitivity for parkinsonism of up to 97% and a specificity for
Table 3 ROC result for discriminating patients with ET from those with all other disease states (i.e.,
PD, MA and DLB)
Threshold for discrimination Sensitivity Specificity Dichotomous Accuracy
Visual > 1 84% 71%* 80%
CSBR < 1.56 82% 85% 83%
PSBR < 0.76 87% 88% 87%
CAQ < 5.12 82% 53%* 74%*
PAQ <=1.70 89% 68%* 83%
Indexed Visual > 0.24 87% 71%* 83%
Indexed CSBR < 0.31 80% 85% 81%
Indexed PSBR <=0.16 82% 91% 84%
Indexed CAQ <=3.65 59%* 79% 64%*
Indexed PAQ <=1.66 85% 74% 82%
*p < 0.05 versus PSBR
Table 4 ROC result for discriminating patients with DLB from those with PD
Threshold for discrimination Sensitivity Specificity Dichotomous Accuracy
Visual > 1 100% 6%* 13%*
CSBR <=0.87 100% 60%* 63%*
PSBR <=0.15 57% 87% 85%
CAQ <=1.71 71% 87% 86%
PAQ <=0.32 71% 86% 85%
Indexed Visual > 0.46 57% 86% 84%
Indexed CSBR <=0.19 85% 66%* 67%*
Indexed PSBR <=0.039 57% 82% 80%
Indexed CAQ <=1.67 71% 88% 87%
Indexed PAQ <=0.41 71% 84% 83%
*p < 0.05 versus Indexed CAQ
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essential tremor up to 100% (Benamer et al., 2000). A normal DaT scan can essentially
exclude a diagnosis of neurodegenerative PS. One study found that 97% of patients with a
normal DaT scan do not have a form of neurodegenerative PS at 3 year follow-up
(Marshal et al., 2009). A DaT scan often changes management, and medication or diagno-
sis changes were seen in 59% of patients following a DaT scan at a major tertiary care
center (Bega et al., 2015).
On the other hand, more than 10% of patients diagnosed with Parkinson’s disease
based on clinical symptoms have normal DaT scans, among whom about 30% have
progressively worsening measureable cognitive impairment 2 years after imaging
(Wyman-Chick et al., 2016). It can be challenging to visually evaluate DaT scans
for patients with ET, considering that DaT scans appear the same for normal
volunteers as for patients with ET; nonetheless, striatal-to-background specific
binding ratios are measurably lower for patients with ET than for normal subjects
(Gerasimou et al., 2012).
Our patients with ET, aged 70 ± 11 yrs. (range: 49–88 yrs), had CSBR of 2.08 ± 0.52 and
PSBR of 1.24 ± 0.42, values that were lower (p < 0.001) than mean published values of 2.5
± 0.3 and 1.9 ± 0.2, respectively, of patients with ET aged 64 ± 11 yrs. (range 28–81 yrs)
(Gerasimou et al., 2012). In part, this reflects the fact that we chose to use minimum
Table 5 ROC result for discriminating patients with DLB from all other patients (i.e., ET, PD
and MA)
Threshold for discrimination Sensitivity Specificity Dichotomous Accuracy
Visual > 1 86% 31%* 34%*
CSBR <=0.87 100% 67%* 69%*
PSBR <=0.15 86% 65%* 66%*
CAQ <=1.71 71% 89% 88%
PAQ <=0.32 71% 88% 87%
Indexed Visual > 0.47 57% 88% 86%
Indexed CSBR <=0.19 86% 72%* 73%*
Indexed PSBR <=0.039 86% 60%* 61%*
Indexed CAQ <=1.67 71% 90% 89%
Indexed PAQ <=0.41 71% 86% 86%
*p < 0.05 versus Indexed CAQ
Fig. 4 Visual scores. a Visual scores plotted for patients with ET, PD, MA and DLB. 4 (b) Indexed visual
scores plotted for patients with ET, PD, MA and DLB
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counts rather than means; our mean caudate SBR’s were 2.3 ± 0.5 and putamen SBR’s
were 1.5 ± 0.4.We chose to use minimum rather than mean counts as these will be more
abnormally low for patients with neurologic disorders. Other investigators have reported
still higher mean values (Yokoyama et al., 2017), with mean CSBR and anterior PSBR
values of 2.8 and 2.3 of a quantitative software package, “DaTQUANT,” for non-
Parkinson’s disease patients aged 26–83. Various methodology differences will likely
produce different mean values for 123I–FP-CIT DaT scan striatal counts at different insti-
tutions. While taking ratios of counts rather than absolute counts should help to provide
some commonality, and use of similar post-injection interval and collimator types also
would help, there are unavoidable differences regarding data processing. Different manu-
facturers implement their reconstruction algorithms with different approaches, assump-
tions, approximations and scaling factors. The reason we chose filtered backprojection
with a Butterworth filter is that the US manufacturer of 123I–FP-CIT continues to recom-
mend this approach, even though reconstruction methods that incorporate collimator
resolution information, such as OSEM, likely produce more reliable striatal count recov-
ery. Comparing results of tomograms processed by FBP to those processed by OSEM
could prove worthwhile, but was beyond the scope of our investigation.
We did not include patient weight and height in our indexing, as some studies have
shown that DaT availability is unrelated to body mass index over a wide range of values
among healthy subjects (Thomsen et al., 2013).
Our retrospective study correlated initial DaT scan results with a reference standard
clinical diagnosis at an average of 1.3 years later. We demonstrated utility of DaT scans
in excluding the diagnosis of a neurodegenerative PS. This is important, as Parkinson’s
disease is often initially overdiagnosed, and unnecessary treatment and patient concern
can be avoided (Marshal et al., 2009; Jennings et al., 2004). In our study, visual analysis
of DaT scans for discriminating between essential tremor and neurodegenerative PS
had 84% sensitivity (Table 3). Sensitivity of visual readings by blinded observers of 95%
has been reported in a multicenter study that included patients with established diag-
noses of Parkinson’s disease and essential tremor (Benamer et al., 2000). However, that
study reported a specificity of 93%, while our study resulted in only 72% specificity.
This may be due in part to the fact that a consensus visual assessment was made
between four nuclear medicine physicians and a neurologist in that study, while in our
study a single experienced nuclear medicine physician evaluated DaT scans, which is
the way these studies typically are interpreted. Another multicenter study, which
involved follow-up of patients with bradykinesia and also rigidity, tremor, or postural
instability and patients with Findley and Koller criteria for definite or probable essential
tremor, reported sensitivity of 78% and specificity of 97% for baseline DaT scans
(Cummings et al., 2011). While our specificity with regard to visual diagnosis is lower
than what is reported in the literature, this may be due partly to lack of inclusionary
criteria for patients in our study. Our specificity may in part reflect the complex and
atypical patient presentations encountered in clinical practice.
Our study also involved quantitative analysis of putamen and caudate counts with
adjustment for background counts. Quantitative parameters are likely affected by patterns
of progressive dopamine loss in Parkinson’s disease, in which the contralateral putamen is
first affected (Marshall & Grosset, 2003; Fearnley & Lees, 1991). This is consistent with a
study involving essential tremor and Parkinson’s disease patients with sequential DaT
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scans (Isaias et al., 2010), in which quantitative analysis revealed overlap between essential
tremor and Parkinson’s disease for caudate uptake, as well as an annual rate of decline of
7.3% for uptake in the contralateral putamen. Additionally, this suggests that quantitative
analysis of the putamen can aid in early diagnosis of Parkinson’s disease, and therefore
allow earlier initiation of treatment, perhaps prior to onset of clinical symptoms.
We found that PSBR ratio < 0.76 was more specific (89%) than visual analysis (72%) in
discriminating between Parkinson’s disease and essential tremor (Table 2). The trend of
increasing specificity with quantitative analysis is consistent with a study comparing initial
DaT scan imaging diagnoses with 6-month clinical follow-up (Jennings et al., 2004), which
reported an increase in specificity from 80% to 100% when utilizing a cutoff of 30% decrease
in age-corrected putamen uptake from normal controls to define abnormal DaT scans.
Quantitative analyses may be important in decreasing the false positive rate of DaT scans.
Our study found that quantification of putamen activity with DaT scans was accurate in dis-
criminating patients with Lewy body dementia from Parkinson’s disease. This is consistent
with a prior study demonstrating a differential pattern of striatal dopaminergic loss between
Lewy body dementia and Parkinson’s disease. Walker, et al., found a significant difference in
caudate binding, with DLB patients demonstrating lower binding than Parkinson’s disease
patients (Walker et al., 2004). They also found a predilection for posterior putamen involve-
ment in Parkinson’s disease when compared to DLB, and that caudate to putamen uptake
ratio was significantly different in Parkinson’s disease patients than in DLB patients.
Limitations
The low numbers of Lewy body dementia patients limits our study. Although clinical
follow-up was obtained through neurology notes, our study did not involve a standardized
clinical assessment for all patients included in the study. Also, as with many prior studies
with DaT scans, our study used clinical follow-up as the diagnostic reference standard,
which intrinsically cannot prove greater accuracy than thorough clinical evaluation itself.
In addition, the caudate and putamen counts in our study were obtained through manu-
ally drawn of regions of interest. Use of standardized segmentation maps would have
reduced uncertainty in the size and shapes of these regions (Nobili et al., 2013).
Conclusions
Our results in this small series of patients with dementia with Lewy bodies suggest that
if 123I–FP-CIT visual scores are to be used to discriminate DLB from other neurologic
disorders, demographic indexing should be applied. However, best results overall are
obtained using quantified parameters, regardless of whether demographic indexing is
applied to these values.
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